Overexpression of DCLK1-AL in pancreatic cancer cells increases cell invasion, drug resistance, and KRAS activation. (a) Both AsPC-1 and MP2 cells were infected with lentivirus containing either DCLK1-AL-RFP or RFP cDNA sequence to establish stable cell lines overexpressing DCLK1. (b) Matrigel coated transwell assays were used to study cell invasion activity. (c) Overexpression of DCLK1-AL increases pancreatic cancer cell resistance to Gemcitabine. (d) DCLK1-AL forms a complex with RAS. (e) Overexpression of DCLK1AL increases active RAS in pancreatic cancer cells. (f-g) Overexpression of DCLK1-AL increases pancreatic cancer cell resistance to Everolimus, ABT-199, and LY-294002.